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CK = cytokeratins  
CTC = circulating tumour cells 
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EpCAM = epithelial cell adhesion molecule 
EpCAMhigh CTC = EpCAM high expressing CTC 
EpCAMlow CTC = EpCAM low expressing CTC 
NSCLC = Non-small cell lung cancer 
tdEV = tumour-derived Extracellular Vesicles 
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Novelty and Impact 
Using a single blood draw, multiple cancer biomarkers as CTC, extracellular tumour vesicles and 
circulating tumour DNA, were analysed in 97 advanced NSCLC patients. The presence of EpCAM high 
expressing CTC and elevated levels of tumour vesicles and tumour DNA were associated with a poor 
clinical outcome, whereas the presence of EpCAM low expressing CTC was not. This single tube 
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Abstract  
The need for a liquid biopsy in non-small cell lung cancer (NSCLC) patients is rapidly increasing. We 
studied the relation between overall survival (OS) and the presence of four cancer biomarkers from a 
single blood draw in advanced NSCLC patients: EpCAMhigh circulating tumour cells (CTC), EpCAMlow CTC, 
tumour derived extracellular vesicles (tdEV) and cell-free circulating tumour DNA (ctDNA). EpCAMhigh 
CTC were detected with CellSearch, tdEV in the CellSearch images and EpCAMlow CTC with filtration after 
CellSearch. ctDNA was isolated from plasma and mutations present in the primary tumour were tracked 
with deep sequencing methods. In 97 patients, 21% had ≥2 EpCAMhigh CTC, 15% had ≥2 EpCAMlow CTC, 
27% had ≥18 tdEV and 19% had ctDNA with ≥10% mutant allele frequency. Either one of these four 
biomarkers could be detected in 45% of the patients and all biomarkers were present in 2%. In 11 out of 
16 patients (69%) mutations were detected in the ctDNA. Two or more unfavourable biomarkers were 
associated with poor OS. The presence of EpCAMhigh CTC and elevated levels of tdEV and ctDNA was 
associated with a poor OS; however, the presence of EpCAMlow CTC was not. This single tube approach 
enables simultaneous analysis of multiple biomarkers to explore their potential as a liquid biopsy. 
Introduction  
Advanced non-small cell lung cancer (NSCLC) patients are characterized by gradual growing metastases 
in different organs, increasing tumour load and comorbidities that grimly determines their fate. Invasive 
diagnostics are often difficult by inability to perform invasive procedures or due to inaccessible 
metastases. Liquid biopsies may provide a convenient and patient-friendly approach to obtain 
information on prognosis and prediction of the best treatment management 1. Liquid biopsy approaches 
include the sampling and analysis of circulating components from blood and other body fluids 2. While 
the clinical utility  of circulating tumour cells (CTC) and cell-free circulating tumour DNA (ctDNA) has 
been extensively investigated in recent years, other components such as tumour derived extracellular 
vesicles (tdEV) have only recently been put to the focus of research 3–7. 
CTC are epithelial cells disseminated into the blood from primary or metastatic sites. The presence of 
CTC is predictive of relatively short survival in several types of cancer, including breast, prostate, colon, 
small and non-small cell lung carcinoma 8–14. CTC are rare events; they are surrounded by ~5·106 white 
blood cells and ~5·109 red blood cells per mL 15,16. For this reason the appropriate marker selection for 
enrichment is a crucial factor. In most cases, CTC detection is based on the expression of the cell surface 
epithelial cell adhesion molecule (EpCAM), as it is expressed by the majority of epithelial derived 
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EpCAM for CTC isolation might lead to an underestimation of CTC numbers because tumour cells 
expressing low amounts of EpCAM might be missed by the system. While EpCAM expressing CTC have 
shown to be highly clinically relevant, recently, the relevance of the presence of CTC expressing no or 
low EpCAM in cancer patients, is the subject of debate. While many subpopulations can be described, 
the clinical utility of these cells is barely addressed 19–23.  
The use of ctDNA as a clinical response marker for NSCLC patients has already moved into the clinical 
routine and EGFR T790M testing from plasma has been proven to complement tissue-based testing 5. 
However, this can be applied to only a subset of patients harbouring an activating EFGR mutation, while 
an untargeted approach, which does not require prior knowledge of the mutation status the tumour, 
would facilitate a more widespread application.  
Tumour derived Extracellular Vesicles (tdEV) comprise of a variety of vesicles secreted or budded of 
from cancer cells and are known to play an important role in many tumour biological processes 7,11,24,25.  
In a previous work we have demonstrated that a subset of tdEV, which expresses both EpCAM and 
cytokeratin but not CD45 or DNA, can be enriched and enumerated using the CellSearch and  their 
presence was strongly associated with poor overall survival 26.  
While all of these biomarkers are promising for predicting survival, the predictive ability of the combined 
biomarkers may yield complementary information and thereby improve diagnostic sensitivity. We 
hypothesized that a comprehensive, multi-parameter approach with different highly specific tumour 
shedding products will predict those patients with a relative good prognosis from those with a poor 
prognosis. Therefore, we determined the presence of four biomarkers in one tube of blood in advanced 
NSCLC patients. Two CTC subpopulations were discriminated: EpCAM expressing CTC (referred to as 
EpCAMhigh CTC) detected using the CellSearch® system and no or low EpCAM expressing CTC (referred to 
as EpCAMlow CTC) detected on microsieves after filtration 21. The tdEV were identified in the images from 
the CellSearch using the open source imaging program ACCEPT, whereas plasma from the same tube 
was used for cell-free ctDNA extraction followed by an untargeted tumour allele fraction analysis 27–29. 
Moreover, for a subset of patients tumour-specific mutations were tracked in plasma DNA using deep 
sequencing or Safe-SeqS 30. In total 97 NSCLC patients were included and the presence of these different 
biomarkers in an all-in-one liquid biopsy was explored.  
Methods 
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Patients with stage IIIB and IV NSCLC were staged according to IASLC staging system (7th Edition) and 
diagnosed using FDG-PET/CT imaging and different techniques to procure tumour tissue. In total 97 
patients were processed: 60 patients were enrolled at University Medical Centre Groningen (The 
Netherlands) and 37 patients at Veneto Institute of Oncology IOV – IRCCS, Padua (Italy). All patients 
provided written informed consent and the study protocol was approved by the medical ethical 
committees. In total 12 different healthy donors donated 35 blood samples, which were used as 
controls and provided informed consent prior to blood donation, in accordance to the study protocol 
approved by the METC Twente ethics committee.  
Blood and plasma collection  
Peripheral blood samples were drawn by vena puncture into 10 mL CellSave blood collection tubes 
(Menarini Silicon Biosystems, Huntingdon Valley PA, USA) and in an additional EDTA blood collection 
tube. EDTA blood collection was performed routinely as part of the diagnostic process that included 
tumour tissue procurement. For CellSearch analysis, the blood from patients was processed within 96 
hours, whereas blood samples from healthy donors were processed within 24 hours. Blood from the 
CellSave tube was transferred to a CellSearch conical tube and centrifuged for 10 minutes at 800g 
without using the brake. Thereafter, plasma was aspirated without disturbing the buffy coat into a 
sterile 2 mL Eppendorf tube and stored at -80°C. For CellSearch CTC enumeration the same volume of 
plasma was replaced with CellSearch Dilution buffer and again centrifuged at 800g for 10 minutes 
without using the brake. Finally, the sample was placed on the CellTracks Autoprep for CTC analysis. 
Plasma from EDTA blood was removed immediately after sampling. Blood from EDTA collection tubes 
was transferred to 15 mL Falcon polypropylene tubes. Samples were centrifuged for 10 minutes at 200g 
at room temperature with both brake settings set to slow and followed by a second centrifugation step 
at 1,600g for 10 minutes. The upper plasma layer was transferred to a Falcon polypropylene tube, 
avoiding contact with the buffy coat layer and again centrifuged at 1,600g for 10 minutes. Afterwards, 
the supernatant was transferred to Eppendorf tubes without disturbing the cell pellet and stored at -
80°C. Circulating DNA from EDTA tubes was extracted within 96 hours. 
Plasma DNA extraction 
A total of 97 patients were included in the study. Plasma from 31 patients was available from two 
different tubes: CellSave tubes and EDTA tubes. These paired samples were used to evaluate differences 
in ctDNA recovery. For the remaining 66 patients plasma was only available from either CellSave (n=23) 
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samples using the QIAamp Circulating Nucleic Acid Kit (Qiagen) including EDTA plasma (n=74) (mean 1.0 
mL, range 0.5-2.0 mL) or CellSave plasma (n=54) (mean 1.7 mL, range 0.8-2.0 mL) and eluted in 60 µL to 
90 µL nuclease-free H2O, depending on the input volume of plasma. Plasma DNA was quantified using 
the Qubit dsDNA HS Assay Kit (ThermoFisher Scientific, Waltham MA, USA). 
Stratification of plasma DNA samples based on tumour fraction using mFAST-SeqS 
Tumour fractions were assessed using the mFAST-SeqS assay, which is based on the selective 
amplification of uniquely mappable LINE1 (L1) sequences and can be used as an overall measure of 
aneuploidy and therefore corresponds to the plasma tumour fraction. L1 amplicon libraries were 
prepared as previously described 29. Briefly, using target-specific L1 primers, 5 µL plasma DNA was 
amplified with Phusion Hot Start II Polymerase for 8 PCR cycles. PCR products were purified with 
AMPure Beads (Beckman Coulter, Brea CA, USA), and 10 µL was directly used for a second PCR with 18 
cycles to add Illumina specific adaptors and indices. L1 amplicon libraries were pooled equimolarly and 
sequenced on an Illumina MiSeq generating 150 bp single reads aiming for at least 100,000 reads. 
Aligned sequence reads were counted and normalized using an in-house script. In order to assess over- 
and under-representation of read counts of each chromosome arm, a z-score statistic was applied by 
comparing read counts to a set of healthy individuals. In order to get a general overview of aneuploidy, a 
genome-wide z-score was calculated by normalizing read counts per chromosome arms and squaring 
and summing them up. Based on previous comparisons with genome-wide z-scores and mutant allele 
frequencies of somatic mutations, a z-score of 5 correlated with a tumour allele frequency of 
approximately 10% 29. Plasma DNA-samples were stratified based on genome-wide z-scores with high 
tumour allele frequency (z-score ≥5) and low tumour allele frequency (z-score <5).  
Tracking primary tumour mutations in of plasma DNA 
In 16 patient samples, in which the mutational status of the primary tumour was available, mutations 
identified in BRAF, EGFR, KRAS and NRAS were tracked in plasma DNA using two deep sequencing 
approaches: conventional deep-Seq and Safe-SeqS. Validation with respect to analytical sensitivity was 
done with reference material harbouring pre-defined variant allele frequencies. To assess specificity we 
additionally sequenced a set of healthy control samples. Since the average error rates of the respective 
EGFR sequence regions were much lower compared to the other hotspots (e.g. 0.02 for EGFR mutations 
in codons T790 and L858 versus 1.36 for KRAS codons 12 and 13), we achieved a maximal sensitivity of 
0.1% for conventional deep sequencing of EGFR without molecular barcodes for error correction. 
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achieved when using Safe-SeqS, which employs molecular barcoding of individual DNA template strands 
to track all sequencing reads back to a single original templates and correct for PCR errors during library 
preparation after error correction. For Safe-SeqS, on average 11.7 ng plasma DNA (range 7.9-20.0 ng) 
was amplified by Phusion polymerase (Thermo Fisher) using amplicon specific primers whereby the 
sense primer contains a 12-base unique molecular identifier (UMI). After 12 cycles of PCR, products 
were purified using Ampure XP beads (Beckman Coulter) and eluted in nuclease-free H2O. In a second 
PCR with 35 cycles, Illumina specific adapters and indices were added. Products were again purified and 
subjected to quality control and quantification on an Agilent Bioanalyzer DNA 7500 chip (Agilent 
Technologies). All samples were pooled equimolarly and sequenced on an Illumina MiSeq in a 2x 150 bp 
paired-end run. Generated reads were then grouped to read families according to the UMI. A consensus 
sequence of each read family and a FastQ-file from this sequence was generated and aligned to the 
human reference genome (hg19) using Burrows-Wheeler transformation, SAMtool and alignments 
visualized in the “Integrative Genomes Viewer” to detect variants. For Deep-Seq, on average 5.2 ng 
(range 3.3-9.6 ng) was used for a target-specific PCR and amplified in 25 cycles using FastStart HiFi 
Polymerase (5 U/µL) followed by a Ampure XB beads (Beckman Coulter) purification. Illumina specific 
adapters and indices were added in a second PCR for 25 cycles. Analysis was performed as described 
above but without collapsing the read to a consensus sequence.  
EpCAMhigh CTC detection by CellSearch  
CTC were enumerated in aliquots of 7.5 mL of blood with CellSearch® Circulating Tumour Cell Kit 
(Menarini Silicon Biosystems). Blood samples were enriched for EpCAMhigh cells and stained with DAPI, 
Cytokeratin-PE and CD45-APC on the CellTracks Autoprep. Image acquisition of the stained cartridges 
was performed on the CellTracks Analyzer II and all images were stored for review by an independent 
trained operator.  
EpCAMlow CTC detection by filtration after CellSearch  
After immunomagnetic selection of EpCAMhigh cells, the CellTracks Autoprep transports the remaining 
blood sample to a waste container. These samples can be used for identification of residual tumour 
cells, as described previously 21. In short, microsieves (VyCAP, Deventer, The Netherlands) were used to 
filter tumour cells from these samples, containing mostly leukocytes and EpCAMlow CTC. The microsieves 
contain 111,800 pores of 5 μm in diameter and are spaced 14 μm apart on a total surface area of 8 by 8 
mm. After filtration, the microsieve was washed once with a permeabilization buffer containing PBS, 1% 
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incubated in this buffer for 15 min at room temperature. Subsequently, a cocktail of fluorescently 
labelled antibodies was used to stain the cells on the sieve for 15 min at 37°C. The staining solution 
consisted of the following monoclonal antibodies: three CK antibody clones targeting CK 4, 5, 6, 8, 10, 
13, 18 (clone C11) conjugated to PE (not commercialized), CK 1-8 (clone AE3) and CK 10, 14, 15, 16 and 
19 (clone AE1), both conjugated to eFluor570 (ThermoFisher Scientific, Waltham, MA, USA), and one 
antibody targeting CD45 (clone HI30) labelled with PerCP (Themo Fisher Scientific). After removal of the 
staining cocktail, the microsieve was washed once and then incubated for 5 min at room temperature 
with PBS/1%BSA and fixed using PBS with 1% formaldehyde (Sigma-Aldrich) for 10 min at room 
temperature. Removal of the fluid during each of the staining and washing steps was performed by 
bringing the bottom of the microsieve in contact with an absorbing material using a staining holder 
(VyCAP). The microsieve was subsequently covered with ProLong® Diamond Antifade Mountant with 
DAPI (Thermo Fisher Scientific). A custom cut glass coverslip of 0.85 by 0.85 cm2 (Menzel-Gläser, 
Saarbrükener, Germany) was placed on both sides of the microsieve for immediate analysis or stored at 
-30°C awaiting further analysis.   
Images covering the entire 0.64 cm2 surface of the microsieves were acquired on a Nikon fluorescence 
microscope equipped with computer controlled X, Y, Z stage, a 20X microscope objective with a NA of 
0.45 and a LED as a light source. The following filters were used: DAPI (DAPI-50LP-A-NQF) with excitation 
377/50 nm, dichroic 409 nm LP, emission 409 nm LP; PE (TRITC-B-NQF) with excitation 543/22 nm, 
dichroic 562 nm LP, emission 593/40 nm and PerCP (FF02-435/40, FF510-Di02 and FF01-676/29 
(customized filter cube)) with excitation 435/40 nm, dichroic 510 nm LP, emission 676/29 nm. All cubes 
were acquired via Nikon (Semrock, Rochester, NY, USA).  
Scoring of CTC by CellSearch and on microsieves 
Analysis of the fluorescent images generated from the CellSearch cartridges was performed according 
the instructions of the manufacturer. Images of EpCAMhigh CTC candidates were identified by the 
CellTracks Analyzer II and presented to an operator for CTC classification. Cell candidates were assigned 
as “CTC” when the objects were larger than 4 µm in diameter, stained with DAPI and CK, lacked CD45 
staining and had morphological features consistent with that of a cell 18. The fluorescent images from 
the microsieves were analysed for identification of EpCAMlow CTC using a plugin for the open-source 
software ICY 31. Operators were asked to annotate every DAPI+/CK+/CD45– event and classify the event 
as a CTC when morphological features were consistent with that of a cell.  
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The CellTracks images from every cartridge were analysed with the open source image analysis program 
ACCEPT (www.github.com/LeonieZ/ACCEPT) 27,28,32. The ACCEPT toolbox detects all events present in the 
images by an advanced multi-scale segmentation approach and extracts several fluorescence intensities 
and shape measurements for every event it has found. The tdEV identified here are relatively large as 
they have been pelleted with the blood cell fraction after centrifugation at 800g. The selection criteria 
used for tdEV were: CK mean intensity ≥60, CK maximum intensity ≥90, CK standard deviation of 
intensity ≥0.15, CK size <150 µm2, CK perimeter ≥3.2 µm (≥5 pixels), CK roundness <0.80 (where 0 is 
perfectly round and 1 is a perfect line), CK perimeter to area <1.1, DNA mean intensity <5, CD45 mean 
intensity <5. Objects that fit the selected definition are depicted in blue, whereas all other objects 
present in the cartridge are depicted in grey. Scatter plots of all parameters for tdEV are presented in 
Supplementary Figure 1. 
Statistical analysis  
Patient variables and EpCAMhigh CTC, EpCAMlow CTC, tdEV and ctDNA data were gathered in an 
independent way and blindly merged into one data set. For EpCAMhigh and EpCAMlow CTC a cut-off of 2 
CTC was used as threshold 18,33. For tdEV the cut-off threshold was set at 18 (see results). A previously 
established cut-off of 5 was used for the genome-wide mFAST-SeqS z-score to estimate high versus low 
tumour allele frequency 29. To determine associations between biomarkers the non-parametric 
Spearman’s Rho correlation coefficient was used. Kaplan-Meier curves for overall survival (OS) were 
constructed and differences between groups were tested by the log-rank test. OS was defined from the 
first diagnosis to death or loss of follow-up. Subsequently, a multivariable Cox regression analysis was 
used to evaluate the discriminative power of favourable (above cut-off threshold) versus unfavourable 
(below cut-off threshold) biomarkers. To analyse the added predictive value of the biomarkers a 
multivariable analysis of changes in concordance index (C-index) was used 34. Statistical analysis was 
performed in SPSS (version 24, SPSS Inc., Chicago IL, USA) and R (R Foundation, Vienna, Austria). A 
nominal p-value <0.05 was considered to be significant.  
Results 
Patients and healthy donors 
In this study, 97 patients with advanced NSCLC, median age of 65 years, with 91% ECOG performance 
score 0-1 and 20% non-smokers were included (Table 1). No difference in survival was found between 
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9.9 months (p=0.693). Healthy donors (n=35) aged 20–55 years and without prior history of cancer or 
blood transmittable disease were used as controls. 
Classification of EpCAMhigh CTC, EpCAMlow CTC and tdEV  
EpCAMhigh CTC were identified in the thumbnail images presented to the operator by the CellTracks 
Analyzer II. The EpCAMlow CTC were manually identified in the images scanned from the microsieves 
with the open source imaging ICY software. Three typical images of EpCAMhigh CTC (panel A), EpCAMlow 
CTC (panel B) and tdEV (panel C) are displayed using the ACCEPT software in Figure 1. In this patient 
sample a total of 40,094 events were detected by ACCEPT. After application of the criteria for an event 
to be assigned as a tdEV, in total 113 objects were identified as a tdEV (panel D).  
Presence of CK positive EpCAMhigh and EpCAMlow cells and tdEV in healthy donors  
In order to assess the specificity of our classification system, blood of 35 healthy donor samples were 
processed for the detection of CK positive EpCAMhigh and EpCAMlow cells and tdEV. While only one 
EpCAMhigh cell was found in a single control sample (2.9%), EpCAMlow cells were detected in five of the 
35 samples (14.3%) (mean 0.2, ±0.5 SD, range 0-2), and of these samples, two samples (5.7%) were on 
the ≥2 CTC threshold. The mean tdEV count in these samples was 5.1 (median 3, range 0-36) with a 
standard deviation (SD) of 6.7. For tdEV, the cut-off threshold was established at 18; based on the mean 
tdEV plus two standard deviations (5.1 + 2*(6.7) = 18.4). One sample was above the ≥18 tdEV threshold. 
Presence of EpCAMhigh CTC, EpCAMlow CTC, tdEV and ctDNA in NSCLC patients  
In 20 patients (21%) ≥2 EpCAMhigh CTC were detected, in 15 patients (15%) ≥2 EpCAMlow CTC, in 29 
patients (30%) ≥18 tdEV and 18 patients (19%) showed high (>10%) tumour allele frequency with 
genome-wide mFAST-SeqS. EpCAMhigh CTC, tdEV and ctDNA were significantly correlated with each 
other, but not with EpCAMlow cells. The frequency distribution is illustrated in Figure 2 and in more detail 
in Supplementary Table S1. ctDNA fraction was determined in the plasma from either the CellSave tube 
(n=23) used for CTC enumeration or from an additional EDTA tube (n=74). Concentration of plasma total 
DNA ranged from 11.9 to 407 ng per mL plasma (mean 69.87 ng/mL) for CellSave tubes and 4.6 to 780.3 
ng per mL plasma (mean 98.7 ng/mL) for EDTA tubes. To determine if CellSave plasma yields different 
ctDNA levels as conventional EDTA plasma, we evaluated the concordance of ctDNA fractions from 31 
patients, of which both tubes were available. Due to the fact that z-scores below 3 cannot be used as 
quantitative measures, only a moderate but significant correlation (r=0.493, p=0.005) was observed 
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(low: 0-5, elevated: 5-10, and high: 10-50), all samples fell into the same category indicating a high 
consistency between the two tubes. 
High resolution analysis of tumour mutation in plasma 
Molecular analysis of the primary tumour was performed in 46 of the 97 (47%) of the patients; however, 
only in 16 patients a specific mutation was detected. Due to the limited sensitivity of mFAST-SeqS and to 
test whether high-resolution sequencing methods can also be applied to CellSave plasma we searched 
for these mutation in plasma. We were able to tracked tumour-specific mutations with ultra-deep 
sequencing in 11 of these 16 patients (69%). Consistent with the low mFASt-SeqS z-scores for these 
patients (range 0.47-3.99) the detected variant allele frequencies (VAF) detected were also low ranging 
from 0.1-5.3%. Detailed information on the mutations and their VAFs, as wells as CTC and tdEV counts, 
for these patients are shown in Table 2.  
Single blood biomarkers and overall survival of NSCLC patients 
To study the discriminative value of the biomarkers NSCLC patients were stratified in those with 
favourable and unfavourable biomarker status according to the threshold cut-off values (Figure 3). 
EpCAMhigh CTC was associated with prolonged overall survival (HR 2.1, 95% CI 1.2-3.7; p=0.014) with a 
median OS of 4.2 months (range 1-21) for the unfavourable group (≥2 CTC) and 12.2 months (range 1-
30) for the favourable group (<2 CTC) (panel A). Secondly, tdEV was associated with overall survival (HR 
2.0, 95% CI 1.2-3.5; p=0.014) with a median OS of 4.2 months (range 1-19) for the unfavourable group 
(≥18) versus 12.2 months (range 1-30) for the favourable group (<18) (panel C). Thirdly, ctDNA was 
associated with overall survival (HR 1.9, 95% CI 1.1-3.4; p=0.032) with a median OS of 5.2 months (range 
1-26) for the unfavourable group with high tumour allele frequency (≥10%) versus 11.5 months (range 1-
30) for the favourable group (tumour allele frequency <10%) (panel D). However, the presence of 
EpCAMlow CTC did not associate with overall survival (HR 1.2, 95% CI 0.6-2.3, p=0.579) with a median OS 
of 6.8 months (range 1-30) for the unfavourable group (≥2 CTC) versus 11.0 months (range 1-29) for the 
favourable group (<2 CTC) (panel B). To study the predictive ability of the four biomarkers, the 
concordance index was calculated. For EpCAMhigh CTC the C-index was 0.561, for EpCAMlow CTC 0.512, 
for tdEV 0.565 and for ctDNA 0.551 (Table 3). 
Comprehensive multi-parameter blood biomarker  
The significant biomarkers from the univariate analysis were EpCAMhigh CTC, tdEV and ctDNA, but not 
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tdEV (0.66), ctDNA (0.35) but not with EpCAMlow CTC (0.08). The correlation between tdEV and ctDNA 
was low (0.25). EpCAMlow CTC was not correlated with tdEV (0.05) or ctDNA (-0.02). To study the 
discriminative power of the three significant biomarkers from the univariate regressions, all were 
simultaneously included as categorical values (favourable and unfavourable) in a multivariable Cox 
proportional regression model. In the model none versus one unfavourable biomarker was not 
significantly different from each other (HR 1.0, 95% CI 0.4-2.1, p=0.909), whereas two (HR 2.3, 95% CI 
1.0-5.0, p=0.038) or all three (HR 2.9, 95% CI 1.4-6.0, p=0.005) unfavourable biomarkers were 
significantly different compared to none unfavourable biomarkers (panel A in Figure 4). Therefore, we 
stratified the patients based on the presence of none and one unfavourable biomarker versus two and 
three unfavourable biomarkers and determined the OS of these two groups (panel B). The patients with 
none and one unfavourable biomarker had a median OS of 12 months (range 1-30) versus 6 months 
(range 1-19) for the patients with two and three unfavourable biomarkers (HR 2.6, 95% CI 1.5-4.6, 
p=0.001). The predictive ability of all three biomarkers in the multivariable C-index model provides a 
significant contribution of 0.575 (p=0.047), but the biomarkers themselves become non-significant. 
When each of the biomarkers were taken of the model, the drop in C-index was extremely small (Table 
3). Moreover, the effect size of each biomarker in the combined model became smaller and non-
significant (EpCAMhigh CTC HR 1.4; tdEV HR 1.5 and ctDNA HR 1.5). 
Discussion 
Blood may contain different tumour derived cells, vesicles and DNA molecules that offer a simple, 
patient friendly approach, to study clone diversity that may be most relevant to determine treatment 
options for patients with advanced NSCLC. In the CANCER-ID consortium (www.cancer-id.eu) CTC and 
tumour related nucleic acids in blood are being extensively explored for their potential to serve as a 
predictive or prognostic factor in advanced NSCLC. In this study, members of this consortium explored 
CTC, tumour derived extra cellular vesicles (tdEV) and plasma nucleic analysis of 97 NSCLC patients 
whether a combined analysis of multiple liquid biopsy components is feasible on the same tube of blood 
and what information could be obtained from such analysis. From the blood collected in 10 mL CellSave 
tubes for subsequent CTC analysis, on average 1.7 mL (0.8-2.0 mL) of plasma could be harvested and 
stored for ctDNA analysis before processing the samples on the CellSearch system. Comparison of the 
CellSave plasma for ctDNA analysis with plasma from EDTA blood showed a strong correlation, indicating 
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For CTC analysis, the FDA cleared CellSearch system was used and in 21% of the advanced NSCLC 
patients CTC were detected. These CTC are referred here as EpCAMhigh CTC and their presence has been 
reported to be associated with poor survival which was confirmed in this study 14,21. We also confirmed 
previous findings that the presence of EpCAMlow CTC, present in 15% of the patients, after filtration of 
the EpCAM depleted blood was not significantly associated with survival 21. This may question the 
cancerous origin of the EpCAMlow CTC. For single cell analysis of these EpCAMlow CTC, technology will 
need to be developed that can determine the molecular composition of these CTC on the microsieves. 
In metastatic prostate cancer, objects smaller than cells expressing cytokeratin and lacking CD45 in the 
EpCAM enriched cell suspensions were associated with poor survival, similarly with CTC in these patients 
26. Using the recently introduced open source imaging program ACCEPT, the identification of these 
objects in CellSearch image sets was automated and in our NSCLC cohort these objects were identified 
with a relatively high density, with elevated levels in 27% of the patients. Moreover, patients with 
elevated tdEV numbers showed significantly worse survival, confirming the earlier observations of a 
strong relation between poor outcome and the presence of tdEV 35.  
For ctDNA analysis we determined the tumour allele frequency in plasma DNA using mFAST-SeqS assay, 
which measures the aneuploidy fraction of circulating DNA 29. It is of note that mFAST-SeqS has a limited 
analytical sensitivity and a correlation of z-scores with tumour allele frequency can only be provided in 
patients with high tumour allele frequency (≥10%). mFAST-SeqS z-scores in the lower range are not 
informative, but indicate a low tumour DNA content. Nevertheless, the intent of this study was not an 
absolute quantification of tumour-derived fragments in plasma but rather the assessment of a fast and 
cost-effective method to stratify patients into groups of high and low tumour allele frequencies and to 
combine these data with other liquid biopsy components. Patients with high tumour allele frequencies 
(19%) had significantly poor survival, similar to elevated EpCAMhigh CTC and tdEV.   
Blood derived tumour markers EpCAMhigh CTC, tdEV and ctDNA in advanced NSCLC were each associated 
with poor survival. Two or three unfavourable biomarkers – all shedding from the tumour – 
discriminates poor prognosis better than one biomarker, but the predictive contribution of each 
biomarker is small, as was shown by the drop in C-index after removing each biomarker from the model. 
We questioned whether there is still room for their own contribution to survival since serious 
collinearity arises with higher correlations between biomarkers. In other words, these biomarkers come 
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survival. However, the lack of power – that is the low number of patients where all three biomarkers 
were present – prohibited significance for the predictive accuracy. 
Although EpCAMhigh CTC, tdEV and ctDNA may be useful to identify a subset of NSCLC patients with a 
relatively poor prognosis, it does not address the question whether information can be retrieved to 
predict whether patients are eligible for targeted therapy. Expression of mutated proteins, such as 
EGFR, can be assessed on CTC and tdEV, but only in those harbouring such mutations (i.e. ~20% of 
patients with advanced NSCLC). In this cohort of patients, mutations in the primary tumour were 
identified in 16 of the 46 NSCLC patients (34%), of whom molecular profiling of the tumor was 
performed. Based on mFAST-SeqS the ctDNA fractions of these patients were very low. The z-scores 
ranged from 0.47-3.99 and were therefore below the dynamic range of this method. However, specific 
mutations can easily be tracked in ctDNA with a much higher analytical sensitivity 36–38.  To test whether 
such ultra-deep sequencing methods can also be applied to CellSave plasma, we tracked tumour-specific 
mutations in these patients.  In 11 of the 16 patients (69%) mutations could be identified in plasma with 
variant allele frequencies ranging from 0.1 to 5.3%, which is consistent with the respective low z-scores. 
Yet, our concordance rate was slightly lower than those reported for metastatic NSCLC patients that 
range between 74-85% 39. However, given our small samples size and the low amount of DNA input 
(which might lead to sampling errors at low variant allele frequencies), our data might not be 
representative. Nevertheless, these data show that the high-resolution assessment of mutations might 
yield in increased ctDNA detection rates, and therefore improve patients stratification based on tumour 
fraction. 
The true potential of a liquid biopsy lies in determining genetic alterations associated with therapy 
resistance or new mutations occurring during the course of the disease. A variety of different liquid 
biopsy approaches have been evaluated for their clinical potential in NSCLC. Due to the low efficiency to 
retrieve high CTC numbers (30% of the patients have 1 or more CTC; 8% with >5 CTC per 7.5 mL blood) 
and elevated plasma DNA tumour fractions all fall short when it comes to a broad patient coverage 33,40–
42. In this study we detected one of the biomarkers in 45% of the patients, whereas each individual 
biomarker was detected in 15-27% of the patients. A potential solution to increase these percentages 
even further is to increase the blood volume that can be analysed which can be obtained through a 
diagnostic leukapheresis 43. Studies in advanced NSCLC are currently being conducted in the CANCER-ID 
consortium to evaluate whether this approach can yield sufficient number of CTC or ctDNA to yield a 










This article is protected by copyright. All rights reserved.
Page 15 of 27 
 
Taken together, here we report for the first time a single tube approach enabling a simultaneous 
analysis of EpCAMhigh CTC, EpCAMlow CTC, tdEV and ctDNA. Except for EpCAMlow CTC, the presence of 
each component was associated with a poor clinical outcome in advanced NSCLC patients. Two or more 
biomarkers discriminated an unfavourable subgroup of advanced NSCLC.  
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Figures and tables 
 
Figure 1 – Gallery of CTC and tdEV 
 Thumbnail gallery of EpCAMhigh CTC from CellSearch (A), EpCAMlow CTC from microsieves (B) and 
EpCAMhigh tdEV from CellSearch (C), showing fluorescent signal for DAPI and/or CK (red circle drawn by 
the ACCEPT software). The scale bar in the overlay thumbnails is 6.4 µm. Panel D shows a scatter plot of 
every object present in the cartridge for characteristics in size (y-axis) and fluorescent mean intensity (x-
axis). The tdEV are identified with a multi parameter gate and are visualized as blue dots. The remaining 
objects that do not fit the multi parameter gate are visualized as grey dots. 
Figure 2 – Frequency distribution of all biomarkers in NSCLC patients 
Frequency distribution of EpCAMhigh CTC, EpCAMlow CTC, tdEV and z-score for ctDNA of 97 NSCLC 
patients. Percentages displayed above the black bar represent the patients that score above the 
threshold for that biomarker.  Thresholds are: two CTC for EpCAMhigh and EpCAMlow, 18 vesicles for tdEV 
and a z-score of 5 for ctDNA, representing approximately 10% mutant DNA alleles. z-score was 
determined in 74 samples from EDTA tubes (open circle) and in 23 samples from CellSave tubes (filled 
circle). 
Figure 3 – Survival plots for each biomarker in NSCLC patients 
Kaplan-Meier plots of probabilities of overall survival of 97 advanced NSCLC patients with favourable or 
unfavourable EpCAMhigh CTC (A), EpCAMlow CTC (B), tdEV (C) and ctDNA (D). To separate between 
favourable and unfavourable groups, the threshold for CTC was 2, for tdEV 18, and for ctDNA 10% 
mutant alleles (z-score of 5). 
Figure 4 – Survival plots for grouped biomarkers in NSCLC patients 
Kaplan Meier plot of probabilities of overall survival of 97 advanced NSCLC patients stratified for the 
amount of unfavourable biomarkers (EpCAMhigh CTC ≥2, tdEV ≥18 and ctDNA ≥10%). Group 0 includes 
patients with no unfavourable biomarkers, group 1 with one unfavourable biomarker, group 2 with two 
unfavourable biomarkers, and group 3 with all unfavourable biomarkers (A). Two groups stratified for 
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Table 1 – Patient demographics 
Characteristics of the patients enrolled in this study. 
 
Stage IIIB and IV non-small lung cancer patients n = 97 
Site location 
 
UMCG, the Netherlands 60 (62%) 
Veneto Institute of Oncology IOV, Italy 37 (38%) 
Age (years) 
 
Median (range)   65 (40-82) 
Gender 
 
Male 47 (48%) 
Female 50 (52%) 
Smoking 
 
Never 19 (20%) 
Smoker 59 (60%) 
Unknown 19 (20%) 
ECOG Performance Status 
 
0 54 (56%) 
1 34 (35%) 
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3 2 (2%) 
4 1 (1%) 
Therapy type 
 
Chemotherapy 41 (42%) 
Targeted therapy 23 (23%) 
Immunotherapy 24 (25%) 
Unknown 10 (10%) 
Cancer type 
 
Adenocarcinoma 59 (61%) 
Squamous cell carcinoma 38 (39%) 
Mean follow-up time in months (min-max) 
 
Alive  16 (4-30) 
Dead 7 (1-25) 
Status at last follow-up 
 
Alive  36 (37%) 

























This article is protected by copyright. All rights reserved.
Table 2 – Tumour mutations located in 16 NSCLC patients
Primary tumour mutations and the shedding of CTC, tdEV and ctDNA in sixteen patients with adenocarcinoma of the lung.








reads VAF %* Method
1 KRAS: c.37 G>T; p.G13C 3 0 52 0.91 16,577 476 2.79 SS
EGFR: p.L747_P753delinsS
2
EGFR: c.2369 C>T; p.T790M
1 6 9 2.06 179,591 0 0.00 DS
3 KRAS: c.38 G>A; p.G13D 1 3 33 3.99 60,274 2,911 4.61 SS
4 KRAS: c.35 G>C; p.G12A** 0 5 5 1.95 48,546 151 0.31 SS
5 ALK: c.3616 T>G;p.S1206A 0 3 2 2.23 410,108 1,179 0.29 DS
6 EGFR: c.2315_2316insGTT; p.P772_H773insF 0 3 0 1.15 430,091 611 0.14 DS
7 BRAF: c.1406 G>T; p.G469V 0 1 17 0.49 45,137 459 1.01 SS
8 NRAS: c.182 A>G; p.Q61R 0 1 1 1.23 36,371 52 0.14 SS
KRAS: c.34 G>T; p.G12C
9
EGFR: c.2305 G>T; p.V769L
0 1 0 2.18 203,64 177 0.09 SS
10 KRAS; c.34 G>T; p.G12C 0 0 14 2.96 166 0 0.00 SS
EGFR: c.2573 T>G; p.L858R 
11
EGFR: c.2369 C>T; p.T790M
0 0 14 0.57 37,493 0 0.00 SS
EGFR: c.2126 A>C; p.E709A 619,082 1,489 0.24
12
EGFR: c.2156 G>C; p.G719A
0 0 10 2.00
620,329 474 0.10
DS
13 KRAS: c.183 A>C; p.Q61H 0 0 5 2.63 10,98 0 0.00 SS
14 EGFR: c.2236_2250del15; p.E746_A750del 0 0 5 0.54 514,839 29,039 5.34 DS
15 EGFR: c.2236_2250del15; p.E746_A750del 0 0 3 0.96 527,145 3,715 0.70 DS
16 EGFR: c.2240_2254del15; p.L747_T751delLREAT 0 0 2 0.47 503,499 5 0.00 DS
* VAF (%) indicates the percentage of variant allele frequency found among the wild type alleles in ctDNA; ** Additional KRAS mutation: c.35G>T; p.G12A 
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Table 3 – C-index for all biomarkers 
Concordance index for biomarkers calculated in a univariate and multivariate setting. 
 
Biomarker (univariate) C-index Biomarkers (multivariate) C-index 
EpCAM
high
 CTC 0.561 EpCAM
high
 CTC & tdEV & ctDNA 0.575 
EpCAM
low
 CTC 0.512 EpCAM
high
 CTC & tdEV 0.570 
tdEV 0.565 EpCAM
high
 CTC & ctDNA 0.575 














This article is protected by copyright. All rights reserved.
